[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608669":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":53,"collaborators":25,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":25,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":25,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1 - CeraVe","EXPERIMENTAL","Subjects who agree to participate in this study and have previously signed a specific informed consent form will enter the maintenance phase with CeraVe emollient following corticosteroid treatment as per clinical practice.",[13],"Other: CeraVe Moisturizing Cream",{"label":15,"type":16,"description":17,"interventionNames":18},"Arm 2 - Galenico","ACTIVE_COMPARATOR","Subjects who agree to participate in this study and have previously signed a specific informed consent form will enter the maintenance phase with a common soft emollient after corticosteroid treatment, as per clinical practice.",[19],"Other: Galenico",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"CeraVe Moisturizing Cream","During the 42-day maintenance phase, subjects must apply the CeraVe emollient twice a day after washing with the basic detergent as part of their normal hygiene routine.",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Galenico","During the 42-day maintenance phase, subjects must apply the emollient twice a day after washing with the basic detergent as part of their normal hygiene routine.",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Prof.ssa Elena Campione","CONTACT","+39 0620908446","elena.campione@ptvonline.it",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":25,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Fondazione PTV - Policlinico Tor Vergata","RECRUITING","Roma","RM","Italy","IT",{"type":45,"coordinates":46},"Point",[47,48],11.10642,44.99364,{"lat":48,"lon":47},[51],{"name":32,"role":33,"phone":52,"phoneExt":25,"email":35},"0620908446",{"type":54,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100608669","cerave-effect-on-restoring-skin-hydration-as-maintenance-regimen-in-subjects-with-mild-to-moderate-atopic-dermatitis-100608669",false,"NCT07204561","CeraVe Effect on Restoring Skin Hydration as Maintenance Regimen in Subjects With Mild to Moderate Atopic Dermatitis","Analysis of the CeraVe Emollient Effect on Restoring the Hydration of the Skin Barrier as Maintenance Regimen in Subjects With Mild to Moderate Atopic Dermatitis","DA_CeraVe","Inclusion criteria:\n\nSubjects with clinically confirmed mild-to-moderate atopic dermatitis (AD), as defined by an Eczema Area and Severity Index (EASI) score of 1-21, whose lesions will clear after treatment with a steroid and who will experience at least a 90% reduction in their EASI score.\n\n\\- Participants of any gender, aged 18 years or over, from any phototype or ethnic group.\n\nParticipants must be willing and able to give informed consent to participate in the study.\n\nExclusion criteria:\n\n* Age \\\u003C18 years. Participants who are unwilling or unable to give informed consent to participate in the study.\n* Receiving any systemic treatment for atopic dermatitis (AD), including corticosteroids, cyclosporine, any approved biologics or JAK inhibitors.\n* Any dermatological disorder which, in the investigator's opinion, may interfere with the accurate evaluation of the subject's skin characteristics (except AD).","ALL","18 Years","99 Years",{"count":67,"type":68},98,"ESTIMATED","INTERVENTIONAL",[71],"NA","This is an open-label, randomised, comparative, prospective, interventional study of a cosmetic product.",[74],"Atopic Dermatitis (AD)","2025-09-24",{"date":77,"type":78},"2025-10-02","ACTUAL",{"date":80,"type":78},"2025-03-25",{"date":82,"type":68},"2026-07",{"name":5,"class":6},1]